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Elastase, a proteolytic enz 
granules of neutrophils, 
tissue injury in emphyse 
phils in the pathophysiology of 
Neutrophils play a critical role in 
ischemia, the stunning of potentially viable myocardium and 
the genesis of a~hythmias elusion in animal models 
of myocardial ischemia (2 vision-related myocardial 
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tinent in interventions (such as thrombolys~s) that restore 
blood flow to jeopardized myocardium and cause entry of 
neutrophils into the ischemic tissue. 
To characterize ne~trophil elastase activity in human 
ischemic heart disease, plasma levels of 
neutrophil elastase-derived fibrin0 
measured in peripheral blood 
angina pectoris, unstable angina 
infarction as well as 
arent cardiovascular 
Stu ts. Ali patients and control subjects were 
male. Patients were recwited consecutively from those 
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presenting for care to the cardiology inpatient or outpatient 
service at the Veterans Affairs Medical Center, Gainesville, 
Florida. Control subjects (n = 22) were outpatients without 
clinical evidence of vascular disease or inpatients hospital- 
ized for evaluation of chest pain, which after evaluation, 
including exercise tolerance testing or CorOnarY angiogra- 
phy, or both, was believed to be noncardiac in origin. 
Diagnosis of stable angina pectoris (n = 25) was based on a 
positive exercise tolerance test and significant coronary 
artery disease documented by coronary angiography without 
recent change in the character, frequency or severity of 
anginal pain. Unstable angina pectoris (n = 29) was defined 
as a change in the pattern of chest pain (recent increase in 
severity or frequency, or both) or new onset of symptoms 
typical of myocardial ischemia, with or without ST changes 
on the electrocardiogram (ECG) and without significant 
elevation in serum creatine kinase (CK). All patients in- 
cluded in the unstable angina pectoris group had typical 
anginal pain at rest. Patients with acute myocardial infarc- 
tion (n = 17) had either elevation in serum CK (>2 times 
normal) or appearance of a new Q wave on the ECG. 
None of the subjects had smoked within 2 h of blood 
collection. Patients taking antibiotics or with a clinical 
history suggestive of underlying infection were not included 
in the study. Written consent to participate in this study, 
which was approved by the Institutional Review Board of 
the University of Florida College of Medicine, was obtained 
from all subjects. 
Blood collection. Peripheral venous blood was collected 
in an acid-citrate-dextrose solution, and the plasma was 
isolated by centrifugation. Blood was collected from all 
subjects within 4 h of hospitalization for peptide BP 30-43 
measurement. In eight patients with acute myocardial in- 
farction, blood was collected at admission and again at 8 and 
16 h after admission for peptide B/3 30-43 and CK measure- 
ments. Total leukocyte and absolute neutrophil counts were 
also determined. 
Assay methods. A radioimmunoassay was developed for 
measurement of a unique fibrinopeptide. Antibodies to the 
peptide Arg-Pro-Ala-Pro.Pro-Pro-Ile-Ser-Gly-Gl~-Gly-Tyr- 
Arg-Ala, produced by the enzymziic cleavage of fibrin or 
fibrinogen by human neutrophil elastase and corresponding 
to the amino acids 30 to 43 of the fibrinogen BP chain (BP 
30-43), were raised in rabbits (5,6). These antibodies exhibit 
high specificity and sensitivity for a fibrinopeptide released 
by the enzymatic degradation of the B/? chain of fibrin or 
fibrinogen by neutrophil elastase (6). 
Significant reactivity of this antibody was noted against a 
larger fibrinopeptide (molecular weight approximately 13 kd) 
released by the action of human neutrophil elastase. This 
peptide is a precursor to the peptide B/l 30-43, is very stable 
in piasma and accounts for most (or all) of the immunoreac- 
GvitY in human plasma. Purified human neutrophil elastase, 
but not Plasmin, liberates this peptide in vitro from both 
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Figure 1. Release of peptide B/3 30-43 (~molfiiter) when fibrinogen 
(Fbg) or fibrin (Fib) is incubated with either human neutrophil 
elastase (E) or plasmin (P). 
fibrinogen and fibrin (Fig. 1). The release of i~~~noreactive 
material is fairly slow and increases with time. Release of the 
13 kd peptide, however, occurs during the first part of the 
incubation period. 
When elastase is added to normal plasma (1450 dml), 
no release of BP 30-43 peptide precursor is obse 
However, after incubation of neutrophil elastase in al 
protease inhibitor-deficient plasma, large amounts of the 
peptide are formed, suggesting that the release of the peptide 
is dependent on this natural inhibitor of elastase. Further- 
more, a synthetic elastase inhibitor, U 25,651 (Stuart Phar- 
maceuticals), strongly inhibits ehe release of the peptide in 
vitro (Fig. 2), demonstratitlg specificity of the radioimmuno- 
assay. 
The antibody has a very low (0. 2%) cross-reactivity 
with fibrinogen. Cross-reactivity with peptides released by 
chymotvypsin, collagen, pancreatic elastase, plasmin, 
thrombin or trypsin is ~0.2%. 
Figure 2. In vitro release of peptide B/3 30-43 is inhibited in the 
presence of U 25,651, a synthetic inhibitor of elastase; 9.4 nmol of 
$asminogen-free fibrinogen was incubated at 37°C with 460 pmol of 
hunlay neutrophil elastase and various concentrations (Cone) of 
inhibitor. 
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e 1. Clinical ~~~acte~i~tic§ of Control and Stu 
COIWOI Stable Lkmlble 
Subjects Aagina hgina AMl 
(n = 22) rin = 25, (n = 79) In = 879 
I 2 2.6 
41 
Hypertension (%) 9 16 ‘1 35 
Diabetes mellitus (%j 5 8 17 17 
edication* (%) 
Nitrates 14 60 16 88 
Beta-blockers 9 32 48 47 
Calcium antagonists 14 9 72 29 
Aspirin 9 48 66 35 
Heparin (iv) 14 0 48 53 
Streptokinase 0 0 tl 18 
*Medication taken within 24 h of blood collection. AMI = acute myocar- 
dial infarction; iv = intwcwusly. 
aspirin, heparin, beta~adre~er~c blockers, nitrates, calcium 
channel antagonists or strepto~i~ase, was assessed in the 
ultiple linear regression. ~onparametric 
Duskal-Wallis and bang-Whitney tests were then used to 
corroborate the findings of the al theory tests. Data are 
expressed as mean values -C S 
Patient characteristics and treatments 
able 1. Approx~~~ately third of all 
rs. Twenty percent to of patients 
had hype~e~sion or d and the ~ropo~io~ was similar 
Iintake of cardiac medication 
s than in the control 
group (p < 0.M). Patients in the control group were younger 
than those in the other study groups (p < 0.05). Analysis of 
relations among factors such as smoking, hypertension, 
10 1 
conlrol 
subjects 
stable unstable 
angIna engIna 
patients patients 
my!xardtet 
lnltwctlon 
patlWltS 
30-43 levels in myocardial &hernia. 
is increased in patients with unstable a 
yocardial infarction as compared wit 
Total leukocyte counts wer 
control subjects (4.9 -C 0.3 x ?+06/ml, p < O.OI for both). 
Absolute neutrophil counts were 
unstable angina (6.6 + 0.7 X 10 
le angina (p < 0.01) but the 
ects did not reach statistical 
There was no significant relation between pep 
levels and total leukocyte count 
p 30-43 levels over 16 h in patients with acute myocardial 
infarction demonstrated a trend toward a decrease over 
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time. Mean peptide B/3 30-43 levels were 1,420 + 669 
pmol/liter at admission, 1,130 f 486 pmolfliter at 8 h and 898 
2 401 pmol/l/ter at 16 h for this group. 
levels were 783 + 570 Wliter at admission, 814 2 331 
W/liter at 8 h and 1,022 + 441 W/liter at 16 h. There was, 
however, no significant relation between peptide B/3 30-43 
levels and serum CK levels at any given time or overall (I’ = 
0.15). 
Role of ncutropbi in acute isc NeutroT:& .I(.; i_. 
mulate in large number myocardium and 
result in capillary plugging and the “no reflow” phenomenon 
(2,8-1(t). These neutrophils undergo activation in response 
to complement fragments and release oxygen free radicals, 
arachidonate metabolites and elastase (2). Tissue damage 
caused by neutrophils during acute ischemic events is char- 
acterized by proteolysis secondary to release of granule 
constituents and free radicals. Specifically, neutrophil 
elastase has been shown to mediate both degradation of 
basement membrane constituents (2) and damage of endo- 
thelium (3). Although much research has focused on the role 
of neutrophil-derived free radical release, the time course of 
neutrophil-mediated endothelial damage more closely re- 
sembles that of the injury caused by neutrophil elastase than 
by oxygen free radicals (4). In this context, our observations 
of significant, severalfold elevations in plasma levels of 
peptide B/3 30-O soon after the onset of unstable angina or 
acute myocardial infarction may have important pathophys- 
iologic implications. 
Relatively higher plasma levels of 
noted in our patients with unstable angi 
pared with those with acute myocardial 
likely due to episodic occlusion and reperfusion of the 
offending coronary artery (1 I), resulting in repetitive entry of 
neutrophils into the ischemic myocardium and their activa- 
tion. In patients with acute myocardial infarction, pharma- 
cologic (in response to streptokinase) or spontaneous reper- 
fusion may cause entry of neutrophils into the ischemic 
tissues. As our study shows, elastase release gradually 
declines over the next 8 to 16 h in patients with myocardial 
infarction, but has no relation to CK release. 
tiitions of the study. Wide variations in the plasma 
levels of peptide B/3 30-43 were observed among our study 
groups, which may relate to the nature of our control grou 
and vagaries inherent in the assignment of clinical labels, 
such as stable and unstable angina pectotis. Subjects in our 
control group, with a ~l”re~n age of 54 years and a 32% 
incidence rate of smoking, are likely to have subclinical 
cardiovascular or pulmonary disease. Previous normat val- 
ues for peptide B/3 30-43 were obtained from normal sub- 
jects, rather than our control patients. This and the assign- 
ment of a value of 50 pmoYliter to all measurements c 100 
values (5-7). 
Hypertension. diabetes me~~itMs 
treatments, which ma 
were also common 
emphysema aud smokiNg (1,12). 
30-43 levels were markedly incr 
our patients with unstable angina 
nn deposits where close contact between fiber 
and elastase may overcome the activity of alohas-protease 
inhibitor). 
With one exception, our 
used for the determination of h 
derived fibrinopeptide in plasma. 
a method for determination of peptide A l-21, derived from 
elastase degradation of fibrino8en. Their method may not be 
generally useful, however, because the antibodies cross- 
react with various other molecul 
Therefore, the peptide has to be is 
liquid chromatography before it ca 
AlthoMgb the 
elevations in peptide BP 30-43 levels in p&ma represent 
increased formation of unique fibrin or ~~~nogen degrada- 
tion products through the a&on of neutrophil elastase, 
whether this increase results from increased substrate (fi- 
disease. 
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